Morningstar Fund Report  | 11/04/2025Print

Wellington Global Health Care Equity Fund USD D Ac

Performance History31/03/2025
Growth of 1,000 (GBP) Advanced Graph
Wellington Global Health Care Equity Fund USD D Ac
Fund2.8-0.5-0.9-1.6-4.7
+/-Cat-6.74.22.3-2.6-3.1
+/-B’mrk-15.5-6.31.7-4.3-6.7
 
Key Stats
NAV
09/04/2025
 USD 41.09
Day Change 2.82%
Morningstar Category™ Sector Equity Healthcare
ISIN IE00B00LSD17
Fund Size (Mil)
10/04/2025
 USD 1672.00
Share Class Size (Mil)
09/04/2025
 USD 551.10
Max Initial Charge 5.00%
Ongoing Charge
21/03/2025
  1.98%
Investment Objective: Wellington Global Health Care Equity Fund USD D Ac
The investment objective of the Fund is to seek long-term total returns. The Investment Manager will actively manage the Fund, seeking to outperform the MSCI World Health Care Index (the "Index”) and achieve the objective, primarily through investment in the equity securities of health care companies worldwide.
Returns
Trailing Returns (GBP)09/04/2025
YTD-10.21
3 Years Annualised-4.10
5 Years Annualised1.91
10 Years Annualised5.22
12 Month Yield 0.00
Management
Manager Name
Start Date
Rebecca Sykes
30/06/2022
Inception Date
30/09/2006

Category Benchmark
Fund BenchmarkMorningstar Benchmark
MSCI World/Health Care NR USDMorningstar Gbl Health TME NR USD
Portfolio Profile for  Wellington Global Health Care Equity Fund USD D Ac28/02/2025
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock98.360.0098.36
Bond0.000.000.00
Property0.000.000.00
Cash2.160.521.64
Other0.000.000.00
Top 5 Regions%
United States74.59
Europe - ex Euro8.59
United Kingdom8.18
Japan4.56
Eurozone2.50
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Eli Lilly and CoHealthcareHealthcare9.82
UnitedHealth Group IncHealthcareHealthcare7.23
Novo Nordisk A/S5.11
AstraZeneca PLCHealthcareHealthcare5.05
Merck & Co IncHealthcareHealthcare4.33
Wellington Global Health Care Equity Fund USD D Ac
Growth Of 1000 (GBP) 31/03/2025
Fund:  Wellington Global Health Care Equity Fund USD D Ac
Category:  Sector Equity Healthcare
Category Index:  Morningstar Gbl Health TME NR USD
Growth of 1,000 GBP
Annual Returns (GBP)31/03/2025
 201820192020202120222023202431/03
Price Return2.3724.4620.332.75-0.47-0.86-1.59-4.74
+/- Category-0.327.442.86-6.684.202.26-2.56-3.12
+/- Category Index----15.46-6.281.68-4.29-6.67
% Rank in Category588307743397780
Trailing Returns (GBP)09/04/2025
   Total Returns   +/- Category   +/- Category Index
1 Day2.82   3.225.22
1 Week-4.45   1.400.53
1 Month-9.73   0.52-0.33
3 Months-13.51   -2.80-4.20
6 Months-16.89   -4.88-4.47
YTD-10.21   -2.31-4.20
1 Year-14.38   -4.19-6.70
3 Years Annualised-4.10   0.68-2.59
5 Years Annualised1.91   -1.60-3.63
10 Years Annualised5.22   -0.05-1.46
 
Quarterly Returns (GBP)31/03/2025
 Quarter 1Quarter 2Quarter 3Quarter 4
2025-4.74---
20246.631.11-2.26-6.62
2023-5.862.51-1.324.11
2022-5.32-0.603.162.51
2021-4.017.39-1.290.98
2020-7.6121.501.605.51
 
 
 
Morningstar Rating™(Relative to Category)31/03/2025
 Morningstar ReturnMorningstar RiskMorningstar Rating™
3-YearAverageAverage3 star
5-YearBelow AverageAverage2 star
10-YearAverageAbove Average2 star
OverallAverageAbove Average2 star
 
Click here to see our Methodology
Volatility Measurements31/03/2025
 
3-Yr Std Dev11.22 %
3-Yr Mean Return-0.16 %
 
3-Yr Sharpe Ratio-0.37
 
Modern Portfolio Statistics31/03/202531/03/2025
 Standard IndexBest Fit Index
 Morningstar Gbl Health TME NR USD  Morningstar Gbl Health TME NR USD
3-Yr Beta1.011.01
3-Yr Alpha-3.46-3.46
 
Investment Style Details28/02/2025
Morningstar Style Box®
Equity Style
SizeRel to Cat
Average Mkt Cap (Mil)USD 61834-
Market Capitalisation% of Equity
Giant30.17
Large30.49
Medium16.98
Small15.35
Micro7.02
Valuations and Growth RatesEquity PortfolioRelative to Category
Price/Prospective Earnings19.510.98
Price/Book3.920.89
Price/Sales1.981.02
Price/Cash Flow14.420.84
Dividend-Yield Factor1.040.78
 
Long-Term Projected Earnings Growth11.091.02
Historical Earnings Growth9.377.29
Sales Growth10.261.07
Cash-Flow Growth-2.940.94
Book-Value Growth7.881.01
 
Asset Allocation28/02/2025
Asset Allocation
 % Long% Short% Net Assets
Stock98.360.0098.36
Bond0.000.000.00
Property0.000.000.00
Cash2.160.521.64
Other0.000.000.00
World Regions28/02/2025
 % of EquityRelative to Category
United States74.591.07
Canada0.541.96
Latin America0.232.45
United Kingdom8.181.54
Eurozone2.500.36
Europe - ex Euro8.590.69
Europe - Emerging0.000.00
Africa0.000.00
Middle East0.000.00
Japan4.561.62
Australasia0.000.00
Asia - Developed0.000.00
Asia - Emerging0.800.64
 
Sector Weightings28/02/2025
 % of EquityRelative to Category
HealthcareHealthcare100.001.03
 
Top 10 Holdings28/02/2025
 Portfolio NEW
Total Number of Equity Holdings86
Total Number of Bond Holdings0
Assets in Top 10 Holdings47.91
NameSectorCountry% of Assets
Eli Lilly and Co206United States9.82
UnitedHealth Group Inc206United States7.23
Novo Nordisk A/SDenmark5.11
AstraZeneca PLC206United Kingdom5.05
Merck & Co Inc206United States4.33
Boston Scientific Corp206United States3.73
Vertex Pharmaceuticals Inc206United States3.42
Edwards Lifesciences Corp206United States3.33
Intuitive Surgical Inc206United States3.15
argenx SE206United States2.75
 
 
Management
Name of CompanyWellington Luxembourg S.à r.l.
Phone-
Websitehttp://www.wellingtonfunds.com
Address33, Avenue de la Liberté
 Luxembourg   L-1931
 Luxembourg
DomicileIreland
Legal StructureOpen Ended Investment Company
UCITSYes
Inception Date30/09/2006
Fund Advisor(s)
Wellington Management Company LLP
Fund ManagerRebecca Sykes
Manager Start Date30/06/2022
Career Start Year2006
 
Biography
Rebecca Sykes is a global industry analyst and portfolio manager at Wellington Management, specializing in pharmaceuticals. Her portfolio management responsibilities include a variety of health care investment vehicles, including a global health care hedge fund, an emerging markets health care fund, and several other long-only health care equity products. She joined Wellington Management in 2007 from Goldman, Sachs & Co. where she was an analyst in the Health Care Investment Banking Group. She earned both her BS and MBA from the Wharton School of the University of Pennsylvania. She holds the Chartered Financial Analyst designation and is a member of the CFA Institute.
Fees and Expenses
Sales Charges (Maximum) 
Max Initial Charge5.00%
Max Exit Charge*n/a
Annual Charges
Max Annual Management Charge1.25%
Ongoing Charge1.98%
Purchase Details
Minimum Investments
Initial5000  USD
Additional1000  USD
Savings-
Tax Free Savings Schemes
ISAsYes